RenovoRx, Inc.

RNXT

$2.37

-5.95%

N/A-$0.15

Healthcare

Biotechnology

NASDAQ

Active Trading

RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is ...

Supply Chain of RNXT

Upstream

Foundry, packaging, memory, wafers, components, and input vendors.

Upstream

Medical Murray, Inc.

Backup/Secondary Contract Manufacturer (Undisclosed)

Aptyx (formerly Argos Corporation)

Specialty Catheter Material Suppliers (Various)

Gemcitabine Drug Suppliers (Generic Market)

Oxaliplatin Drug Suppliers (Generic Market)

Medical Murray, Inc.

Single-source principal contract manufacturer of RenovoCath® dual-balloon infusion catheter devices. Located in North Barrington, IL. Privately owned medical device contract manufacturer specializing in complex catheters.

Backup/Secondary Contract Manufacturer (Undisclosed)

Backup catheter manufacturer engaged as of 2025-2026 to mitigate single-source risk. Name not publicly disclosed in SEC filings.

Aptyx (formerly Argos Corporation)

Tier 2 supplier to Medical Murray. Aptyx acquired Medical Murray's Charlotte, NC facility in January 2025 and provides plastic injection molding components and precision extrusion services for catheter manufacturing.

Specialty Catheter Material Suppliers (Various)

Suppliers of medical-grade polymers, balloon materials, hub components, and catheter shaft materials used by Medical Murray in RenovoCath production. Specific vendors not publicly named by RenovoRx.

Gemcitabine Drug Suppliers (Generic Market)

Unconfirmed

Supply of gemcitabine hydrochloride, a generic chemotherapy, used as the active pharmaceutical ingredient in RenovoGem™ (IAG) for the Phase III TIGeR-PaC trial. Procured from generic pharmaceutical manufacturers (e.g., Pfizer, Fresenius Kabi, Hikma, Sandoz, Teva - no specific disclosed relationship).

Downstream

Customers, distributors, OEMs, and channels that absorb output.

Downstream

City of Hope Cancer Center

Moffitt Cancer Center

SCRI Oncology Partners (Sarah Cannon Research Institute)

Johns Hopkins Medicine

Atrium Health - Levine Cancer Institute

Additional 11+ Active U.S. Cancer Centers (Undisclosed)

Imugene Limited

Direct Sales Model (No Intermediary Distributors)

City of Hope Cancer Center

Active commercial cancer center customer using RenovoCath® device for targeted drug delivery procedures. NCI-designated comprehensive cancer center based in Duarte, CA.

Moffitt Cancer Center

Active commercial cancer center customer using RenovoCath® device. NCI-designated comprehensive cancer center based in Tampa, FL.

SCRI Oncology Partners (Sarah Cannon Research Institute)

Clinical trial site and commercial customer. Enrolling patients in the Phase III TIGeR-PaC trial in Nashville, TN. Part of the US Oncology Network / McKesson.

Johns Hopkins Medicine

Clinical trial site and commercial customer. Initiated patient enrollment for TIGeR-PaC Phase III trial (announced April 2025).

Atrium Health - Levine Cancer Institute

Clinical trial site and commercial customer for RenovoCath. Based in Charlotte, North Carolina.

Proxies

Public comparables and monitoring names used as representatives for the analysis.

Proxies

Boston Scientific Corporation

AngioDynamics, Inc.

Imugene Limited

Boston Scientific Corporation

NYSE:BSX

Strategic investor in RenovoRx (led $10M Series B in 2018). Operates in interventional oncology and interventional cardiology. BSX's BTG subsidiary has interventional oncology portfolio. Direct strategic alignment and inside knowledge of RenovoRx's technology and market opportunity.

AngioDynamics, Inc.

NASDAQ:ANGO

Publicly traded medtech company in interventional oncology with catheter-based tumor ablation and drug-delivery platforms. Comparable business model targeting the same interventional oncology physician base and hospital customers. Can serve as a public market proxy for commercial-stage valuation benchmarks.

Imugene Limited

ASX:IMU

Direct research collaboration partner with RenovoRx evaluating oncolytic virus delivery via TAMP platform. Both are clinical-stage oncology companies. IMU's market performance and partnership success provide indirect read-through for RenovoRx's platform value.

Geographic

Region-level exposures that can distort the supply network.

Geographic

United States

United States (Illinois)

All 16 active U.S. cancer center customers

Medical Murray, Inc.

United States

Single-country commercial and operational concentration

All 16 active U.S. cancer center customers100% of RenovoCath commercial revenue derived from U.S. cancer centers. No international sales or regulatory approvals.

Medical Murray, Inc.Sole manufacturer located in North Barrington, IL (HQ) with additional facilities in Lake Zurich, IL. All production within the United States.

United States (Illinois)

Manufacturing geographic concentration

Medical Murray, Inc.All RenovoCath catheter manufacturing occurs at Medical Murray facilities in North Barrington and Lake Zurich, Illinois. Single-state manufacturing risk.

Concentration

Customer, supplier, or partner concentration exposures that can distort the supply network.

Other

Critical

Single-source contract manufacturer dependency: RenovoRx relies on Medical Murray, Inc. as the sole manufacturer of RenovoCath catheters. While a backup manufacturer has been engaged, any disruption at Medical Murray (capacity, quality, regulatory) could materially impact RenovoRx's ability to supply its only commercial product.

Customer

High

Early-stage commercial concentration: With only 16 active cancer center customers as of Q1 2026 generating $1.1M in FY2025 revenue, the customer base is narrow and unproven. Growth depends entirely on adoption by additional cancer centers.

Other

Critical

Clinical-stage pipeline dependency: The company's long-term value depends on the success of the Phase III TIGeR-PaC trial (enrollment completion expected H1 2026, data 2027). Failure would severely impact the drug/device combination thesis.

Other

High

No drug revenue diversification: RenovoRx has no approved drug product. RenovoGem (IAG) is investigational only. Revenue is solely from RenovoCath device sales, which is an early-stage commercial product.

Foundry

High

Catheter manufacturing technical risk: The RenovoCath is a specialized dual-balloon infusion catheter. Any manufacturing quality issues, FDA compliance findings, or supply chain interruptions for specialized materials could halt production.

Revenue mix

How the target's revenue mix translates into supply-chain leverage and dependency.

RenovoCath® Device Commercial Sales

100.0%

$0.0B

All revenue derives from direct sales of RenovoCath catheters to U.S. cancer centers. The catheter is the sole commercial product, manufactured by a single-source contract manufacturer. Revenue is early-stage (first full commercial year 2025). No drug revenue yet as RenovoGem remains investigational in Phase III.

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer